MedTrace Logo

A Study to Assess the Safety of MEDI7836 in Healthy Adults.

NCT02388347 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 79

Last updated 2017-05-16

Study results available
· View outcomes & findings →

Summary

To assess the safety of a single ascending dose of MEDI7836 in healthy adult male subjects and healthy adult female subjects of non-childbearing potential.

Conditions

  • Healthy Adults

Interventions

DRUG

Placebo SC

Participants will receive a single-dose of Placebo subcutaneous (SC) injection on Day 1.

BIOLOGICAL

MEDI7836 Dose 1

Participants will receive a single-dose of MEDI7836 Dose 1 SC injection on Day 1.

BIOLOGICAL

MEDI7836 Dose 2

Participants will receive a single-dose of MEDI7836 Dose 2 SC injection on Day 1.

BIOLOGICAL

MEDI7836 Dose 3

Participants will receive a single-dose of MEDI7836 Dose 3 SC injection on Day 1.

BIOLOGICAL

MEDI7836 Dose 4

Participants will receive a single-dose of MEDI7836 Dose 4 SC injection on Day 1.

Sponsors & Collaborators

  • MedImmune LLC

    lead INDUSTRY

Principal Investigators

  • Annelize Koch, MD · Parexel

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
50 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2015-03-31
Primary Completion
2016-01-31
Completion
2016-04-30

Countries

  • United Kingdom

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02388347 on ClinicalTrials.gov